NTRA
T2Natera, Inc.
Biotech '26: Established PharmaData Owners '25: Healthcare, Claims & Clinical DataGenomics '25: Molecular Diagnostics & Clinical GenomicsMedTech Long '26: Diagnostics & Early Detection
Loading chart…
OverviewNatera, Inc. develops and commercializes molecular diagnostic tests. Its portfolio includes Panorama for prenatal screening, Prospera for organ transplant rejec
Natera, Inc. develops and commercializes molecular diagnostic tests. Its portfolio includes Panorama for prenatal screening, Prospera for organ transplant rejection monitoring, and Signatera for personalized, tumor-informed cancer recurrence monitoring. The company sells to healthcare providers and laboratories globally, experiencing strong growth, particularly in its oncology segment with recent FDA and international approvals.
Search Keywords Brand Product
- Panorama NIPT
- Signatera MRD
- Prospera transplant test
- Fetal Focus
- Latitude ctDNA
- Renasight kidney panel
- Horizon carrier screening
- Spectrum IVF
- Anora miscarriage analysis
- Constellation software
- molecular diagnostics
- non-invasive prenatal testing
- NIPT
- organ transplant rejection
- circulating tumor DNA
- ctDNA
- molecular residual disease
- MRD testing
- early cancer detection
- genetic testing
- companion diagnostic
Search Keywords Event Phrases
- Natera earnings
- Q2 2026 results
- FIND study enrollment
- SIGNAL-ER101 trial launch
- Japan Signatera launch
- bladder cancer approval
- colorectal cancer approval
Search Keywords Policy Regulatory
- FDA approval diagnostics
- PMDA approval Japan
- NCCN guidelines cancer
- MolDx coverage
- Medicare reimbursement diagnostics
- IVDR certification EU
- biomarker state laws
- What They Do (Plain English & Analogies)
- Natera is a diagnostics company that develops and sells advanced genetic tests using a blood sample. Think of them as a high-tech detective agency for your body's DNA. They primarily focus on three areas: 1) **Women's Health**: Helping expectant parents understand the genetic health of their baby during pregnancy, like screening for chromosomal abnormalities or inherited conditions. They also offer paternity testing. 2) **Organ Health**: Monitoring patients who have received organ transplants to detect early signs of rejection, much like a constant watchful eye to ensure the new organ is doing well. 3) **Oncology (Cancer)**: Using a blood test to detect tiny fragments of cancer DNA (called circulating tumor DNA or ctDNA) after surgery or during treatment. This helps doctors see if any cancer cells are left behind, if the cancer is coming back, or how well a treatment is working, acting like a highly sensitive radar for cancer. They also provide a cloud-based platform for labs to develop their own tests.
- Very Brief History
- Natera, Inc. was founded in 2003, initially known as Gene Security Network, Inc., before changing its name to Natera, Inc. in 2012. The company has since grown to become a leader in molecular diagnostics, particularly in non-invasive prenatal testing, organ transplant assessment, and molecular residual disease monitoring in oncology, driven by continuous innovation and significant investment in clinical evidence.
- "Street Stereotype"
- Natera is generally perceived as the industry titan and leading innovator in molecular residual disease (MRD) monitoring, particularly with its Signatera test. Investors and analysts view the company as having a strong competitive moat due to its extensive clinical evidence, regulatory approvals, and advanced technology, positioning it at the forefront of early cancer detection and personalized medicine.
- Subsidiaries On Linked In*
- Foresight Diagnostics — Acquired subsidiary operating a CLIA-certified lab in Boulder, Colorado.
- Customer Sectors & Example Clients
- Natera's customers are primarily in the healthcare sector, including: **Oncology**: Oncologists, cancer centers, and biopharmaceutical companies. **Women's Health**: OBGYNs, maternal-fetal medicine specialists, and fertility clinics. **Organ Health**: Transplant surgeons, nephrologists, cardiologists, pulmonologists, and transplant centers. Specific biopharmaceutical partners mentioned include Chugai (in Japan for bladder cancer), Exelixis, and Merck (MSD) for clinical trials using Signatera, and Kupando Therapeutics for a Phase 1 immunotherapy trial using Latitude.
- New Customers / Segments They'Re Targeting
- Natera is actively targeting several new customer segments and expanding its reach. In women's health, they are winning new accounts with their enhanced Panorama test, which addresses a previous gap in reliable performance at low fetal fraction. In oncology, they are driving broader adoption of Signatera across various tumor types, including colorectal and breast cancer as their largest indications, and expanding into a 'long tail' of other histologies. The company is also focused on increasing adoption among physicians who await NCCN recommendations and securing new positive coverage policies from commercial payers. Geographically, they are targeting the Japanese market for Signatera in colorectal and bladder cancer, and expanding across the EU with IVDR certification for Signatera. A significant long-term target is the early cancer detection market with their FIND study, aiming to launch a genuinely differentiated product for average-risk adults.
- Supply Chain And Sourcing Geographies
- The provided information does not explicitly detail Natera's supply chain or the specific geographies from which its products or components are sourced. However, Natera operates ISO 13485-certified and CAP-accredited laboratories certified under CLIA in Austin, Texas, and San Carlos, California, and through its subsidiary Foresight Diagnostics, in Boulder, Colorado, where its tests are processed.
- Sales Geographies And Expansion Plans
- Natera currently sells its products primarily in the **United States**, as evidenced by discussions of Medicare, MolDx coverage, NCCN guidelines, and biomarker states. The company has significant plans for international expansion: they are launching Signatera in **Japan** for colorectal cancer, with a commercial launch expected later this year pending pricing and reimbursement, and have submitted for approval in bladder cancer. Additionally, Signatera has received IVDR certification in the **EU** across more than 20 tumor types, which streamlines future clinical trial launches and sets Natera up for future reimbursement in Europe.
- How Key Themes May Help/Hurt
- Natera is strongly positioned within the 'MedTech Long '26: Diagnostics & Early Detection' theme, which can both help and hurt its trajectory. **Help**: The accelerating technological advancements in genomics and multiomics directly benefit Natera's core business, as their tests like Signatera and Panorama leverage cutting-edge cell-free DNA and SNP-informed deep sequencing. The increasing global prevalence of cancer and chronic diseases, coupled with an aging population, creates a sustained and growing demand for advanced diagnostic solutions like MRD testing and organ transplant surveillance. Favorable regulatory developments, such as FDA approvals, NCCN guideline inclusions, and expanded Medicare coverage (e.g., for Prospera), are enhancing market access and accelerating adoption for Natera's products. **Hurt**: Persistent reimbursement pressures and evolving payer policies, including the time it takes for new coverage decisions to impact average selling prices (ASPs), can affect profitability. Intensifying competition from both established players and new entrants in the liquid biopsy and MRD space may lead to pricing pressures and increased commercialization costs. While not explicitly stated as a hurt, the significant R&D investment, particularly in early cancer detection, represents a substantial cash burn without immediate top-line benefits, which could be a drag if market adoption or regulatory pathways are delayed.
3 Main Long-Term Bull Details
- Leadership in Molecular Residual Disease (MRD) with Robust Evidence and Regulatory Wins: Natera's Signatera test is a leader in MRD, backed by extensive prospective clinical studies (over 70), multiple regulatory approvals (US FDA as a companion diagnostic, Japanese PMDA, EU IVDR certification), and Category 1 NCCN guideline recommendations across several tumor types. This strong evidence base and regulatory validation create a significant competitive moat and drive increasing adoption and reimbursement.
- Diversified Growth Engines in High-Value Diagnostics: Beyond oncology, Natera demonstrates strong performance and innovation in women's health (e.g., enhanced Panorama, Fetal Focus, RHD test) and organ health (Prospera, with expanded Medicare LCD coverage). These segments provide diversified revenue streams and continued growth opportunities, leveraging their core cell-free DNA technology.
- Significant Future Opportunity in Early Cancer Detection: Natera is making substantial investments in its early cancer detection program, with the pivotal FIND study approaching full enrollment. The company believes it is developing a genuinely differentiated product designed for high sensitivity for advanced adenomas, positioning it for a potentially enormous future market that could scale to millions of tests per year.
3 Main Long-Term Bear Details
- Persistent Reimbursement Hurdles and ASP Volatility: Despite progress, Natera continues to face challenges in securing consistent and optimal reimbursement for its novel tests, particularly Signatera. Achieving the long-term target ASP of $2,000 depends on additional MolDx coverage decisions and broader guideline inclusion, which can be slow and unpredictable, impacting profitability.
- High R&D Investment with Delayed Returns for Early Cancer Detection: Natera is making a substantial investment (approximately $100 million in 2026) in its early cancer detection program, which currently yields no top-line or margin benefits. While promising, this significant spend without immediate revenue generation creates a cash burn and relies on successful clinical trial readouts and regulatory approvals in the future.
- Intensifying Competition and Market Education Challenges: The diagnostics market, especially for MRD, is becoming increasingly competitive with multiple players. While Natera maintains a strong position, the need for continuous market education, differentiation, and securing payer coverage in a crowded field can lead to ongoing commercialization costs and potential pressure on market share and pricing.
- Competitors And Differentiation
- Natera faces competition from other molecular residual disease (MRD) competitors and major oncology diagnostics companies. While specific competitors are not named in the transcript, the broader theme context mentions companies like Guardant Health (Reveal MRD), Personalis (NeXT Personal), and NeoGenomics (RaDaR MRD). Natera differentiates itself through several key aspects: **Technology**: They utilize novel SNP-informed deep-sequencing technology (Panorama) and a personalized tumor-informed multiplex PCR NGS assay (Signatera), enhanced by phase variant technology acquired from Foresight Diagnostics. **Extensive Clinical Evidence**: Natera has built a robust clinical evidence engine with over 70 prospective studies, leading to significant milestones like FDA approval for Signatera as a companion diagnostic in muscle-invasive bladder cancer, Japanese PMDA approval for colorectal cancer, and IVDR certification in the EU. They have also secured Category 1 NCCN guideline recommendations for Signatera in bladder cancer, Merkel cell carcinoma, and diffuse large B cell lymphoma. **User Experience**: Investments in reducing tissue-related issues, expanding sample acceptance, and mobile phlebotomy. **Commercial Strength**: A significant investment in the size and breadth of their commercial and medical affairs teams, which is now yielding strong performance.
- Recent Performance & What The Market'S Focused On
- Natera had an exceptional second quarter of 2026, processing approximately 1.044 million tests, a new company record, and generating $753 million in revenue, representing 38% year-over-year growth (40% ex-revenue true-ups). Clinical MRD units grew 56% year-over-year and 34,000 units sequentially, the largest sequential increase to date. Gross margins were strong at approximately 65%, driven by sequential ASP improvements. The company also generated positive cash inflow and narrowed operating losses. Natera significantly raised its full-year 2026 revenue guidance to $2.85 billion to $2.91 billion, implying 31% revenue growth ex-true-ups. The market is primarily focused on the continued strong volume growth of Signatera, the trajectory of its ASPs (with expectations for further increases from MolDx coverage and NCCN guidelines in 2027), and the progress of the early cancer detection program (FIND study enrollment and future readouts). The impact of new product launches in women's health (enhanced Panorama, Fetal Focus) and organ health (Prospera's expanded Medicare coverage) are also key areas of attention.
- Revenue Segments And Estimated Mix
- Oncology (primarily Signatera) — Mix: Largest and fastest-growing segment; Source: Q2 2026 transcript; Trend: Clinical MRD units grew approximately 56% year-over-year; 34,000 sequential unit increase over Q1 2026. Signatera ASPs up to ~$12.75.
- Women's Health — Mix: Significant segment; Source: Q2 2026 transcript; Trend: High-single-digit growth versus Q2 2025 on a seasonally adjusted basis, driven by new account wins and enhanced Panorama launch.
- Organ Health — Mix: Growing segment; Source: Q2 2026 transcript; Trend: Strong quarter, volume continued to ramp, expected benefit from expanded Medicare LCD in H2 2026.
- Product Brands
- Panorama
- Vistara
- Horizon
- Spectrum
- Anora
- Signatera
- Prospera
- Constellation
- Fetal Focus
- Latitude
- Signatera genome
- enhanced Panorama
- Renasight
Bull / Bear DetailsNatera, a leader in molecular diagnostics, is poised for continued growth, driven by the exceptional performance and expanding clinical utility of its Signatera
Thesis
Natera, a leader in molecular diagnostics, is poised for continued growth, driven by the exceptional performance and expanding clinical utility of its Signatera MRD test, bolstered by recent FDA, PMDA, and NCCN approvals. Strategic investments in a robust clinical evidence pipeline, new product launches in women's and organ health, and a strong revenue outlook for 2026 underpin a compelling long-term investment case, despite ongoing reimbursement and competitive dynamics. (As of 2026-08-15)
Bull case
Signatera's industry-first FDA approval as a companion diagnostic, Japanese PMDA approval, and a Category 1 NCCN recommendation for muscle invasive bladder cancer validate Natera's personalized MRD technology. These significant regulatory and guideline achievements are driving substantial commercial adoption, new account wins, and solidifying Natera's leadership in the rapidly expanding oncology diagnostics market, as evidenced by 56% YoY growth in clinical MRD units.
Natera's extensive investment in over 70 prospective clinical studies, including the new interventional SIGNAL program for breast cancer, is entering a 'harvest phase' with accelerating readouts. This robust evidence generation, coupled with 7 MolDx submissions for Signatera and the pivotal FIND study for early cancer detection, creates a strong pipeline for future market expansion, guideline inclusion, and significant ASP growth, with a long-term target of $2,000.
Beyond oncology, Natera demonstrates strong performance in women's health with the enhanced Panorama test driving new account wins and in organ health with expanded Medicare coverage for Prospera. The company's ability to maintain high gross margins (65%) while investing in new products, coupled with a clear roadmap for COGS optimization, supports sustained profitability and financial strength, with a long-term gross margin target of 70%+.
Bear case
Despite recent ASP improvements for Signatera, achieving the long-term $2,000 target is contingent on future MolDx coverage decisions and broader guideline inclusion, which are hard to forecast with precision. The current revenue guidance assumes stable ASPs for the rest of 2026, indicating that significant ASP uplifts from new coverages may not materialize immediately, posing a risk to near-term profitability and revenue growth.
While Natera acknowledges its strong position, the MRD market is attracting increasing competition from established players with MolDx-approved tests and new entrants. Although Natera's penetration is still in the mid-single digits, intensifying competition could lead to pricing pressures, increased commercialization costs, and potential erosion of market share, particularly as competitors also generate clinical evidence.
Natera's aggressive investment in R&D, particularly the $100 million allocated to the early cancer detection (ECD) FIND study, represents a significant cash outlay that currently yields no top-line or margin benefits. While promising, the ECD market is nascent and carries inherent regulatory, clinical, and commercialization risks, and the 'growth wave' to millions of tests per year is still several years away, impacting near-term profitability.
Bull / Bear Case
- Bear Case
- Despite strong volume growth, Natera faces significant near-term challenges, particularly regarding the realization of its long-term $2,000 Signatera ASP target. Management's guidance for stable ASPs in the latter half of 2026 indicates that substantial ASP uplifts from MolDx coverage decisions and broader guideline inclusion are not immediate and remain hard to forecast with precision, posing a risk to near-term profitability. The aggressive $100 million investment in the early cancer detection (ECD) FIND study represents a considerable cash outlay that currently yields no top-line or margin benefits, impacting current profitability and free cash flow. Furthermore, the molecular residual disease (MRD) market is attracting increasing competition from established players and new entrants, which could lead to pricing pressures, higher commercialization costs, and potential erosion of market share, despite Natera's current leadership position.
- Bull Case
- Natera is poised for continued leadership and growth, driven by the exceptional performance of its Signatera MRD test, which saw 56% YoY growth in clinical MRD units and a record 34,000 sequential unit increase. Recent industry-first FDA approval as a companion diagnostic, Japanese PMDA approval, and a Category 1 NCCN recommendation for bladder cancer validate its technology and are accelerating commercial adoption. The company's extensive investment in over 70 prospective clinical studies, including the new interventional SIGNAL program, is entering a 'harvest phase,' promising future market expansion, guideline inclusion, and significant ASP growth towards a long-term target of $2,000. Diversified growth in women's health (enhanced Panorama) and organ health (expanded Medicare for Prospera), coupled with a clear roadmap for COGS optimization and a long-term gross margin target of 70%+, further strengthens the bull case. The pivotal FIND study for early cancer detection also represents an enormous future market opportunity.
- More Compelling & Why
- Bear. Natera's current valuation, with a Price/Sales ratio around 10x and negative Free Cash Flow, appears stretched given the significant R&D investment in early cancer detection ($100M in 2026) that yields no immediate top-line or margin benefits. The strongest bear argument is the near-term uncertainty of achieving the long-term $2,000 Signatera ASP target, as management guided for stable ASPs in H2 2026 and major uplifts are contingent on unpredictable MolDx decisions in 2027. My view would flip to Bull if Natera demonstrates consistent, material sequential ASP increases for Signatera in the coming quarters, signaling faster-than-expected reimbursement and MolDx coverage traction.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| Signatera Average Selling Price (ASP) Sequential Increase | Improvements in Signatera's ASP directly enhance Natera's profitability and reflect increasing reimbursement consistency from Medicare Advantage and commercial payers, validating the test's value proposition. | Sequential increase in Signatera ASP for Q3 2026 compared to Q2 2026 (Q2 2026 ASP was approximately $12.75). Management suggested an upside case of another $25 sequential increase in the near term. | A sequential ASP increase of $25 or more for Signatera is a bullish signal for near-term revenue and margin expansion; an increase below $25 would indicate slower tactical reimbursement progress. | Natera's Q3 2026 earnings conference call and press release, expected in late October/early November 2026. | Industry news and reports on Medicare Advantage and commercial payer coverage policies for personalized ctDNA MRD tests. | Komodo Health / Symphony Health: Analysis of Natera Signatera reimbursement rates and payer mix. |
| MolDx Coverage Decisions for 7 Submitted Signatera Indications | MolDx coverage for additional Signatera indications is a significant catalyst for expanding the addressable market and substantially increasing the long-term ASP, driving significant revenue growth and market penetration. | Announcements of MolDx Local Coverage Determinations (LCDs) for any of the 7 submitted Signatera indications over the next 12-18 months. | Approval of any of the 7 MolDx submissions is a bullish signal, potentially adding $150-$200 to the long-term ASP; delays or rejections would be a bearish signal. | Natera press releases, SEC filings, and MolDx website (www.mol.dx.com) for LCD updates. Expected rolling approvals over the next 12-18 months. | MolDx website (search for Natera or Signatera LCDs), industry news outlets covering diagnostic reimbursement. | Advisory Board / Decision Resources Group: Payer policy tracking and analysis for molecular diagnostics. |
| Completion of Enrollment for the FIND Study (Early Cancer Detection) | Completing enrollment for the pivotal FIND study is a critical de-risking milestone for Natera's early cancer detection program, paving the way for data readout and potential market entry into a massive, high-growth segment. | Official announcement from Natera regarding the full enrollment of approximately 24,000 average-risk adults in the FIND study, expected in Q3 2026. | Completion of enrollment in Q3 2026 is a bullish signal, indicating the program is on track for a 2027 readout and future commercialization; delays beyond Q3 2026 would be a bearish signal. | Natera press releases, SEC filings, and the Q3 2026 earnings conference call. ClinicalTrials.gov (NCT05041416) for study status updates. | ClinicalTrials.gov: Monitor recruitment status for NCT05041416 ('FIND: A Study to Evaluate the Performance of a Multi-Cancer Early Detection Test'). | Thinknum: Natera R&D job postings related to early cancer detection or 'FIND study' for hiring trends. |
| Signatera Clinical MRD Unit Sequential Growth | Strong sequential growth in Signatera clinical MRD units indicates robust market adoption, effective commercial execution, and expanding clinical utility, directly driving Natera's revenue and market share in the oncology diagnostics segment. | Sequential growth in clinical MRD units for Q3 2026 compared to Q2 2026 (Q2 2026 saw 34,000 sequential units, previous record was 25,000). | Sequential growth of Signatera clinical MRD units exceeding 25,000 units indicates bullish momentum; growth below 25,000 units would signal a slowdown. | Natera's Q3 2026 earnings conference call and press release, expected in late October/early November 2026. | Google Trends: 'Signatera MRD', 'Natera oncology test' search volume trends. | Thinknum: Natera sales and medical affairs job postings growth/decline. |
| Launch of Additional SIGNAL Program Interventional Studies | The launch of more interventional SIGNAL studies across major tumor types demonstrates Natera's commitment to generating practice-changing evidence, which is crucial for driving future guideline inclusions, reimbursement, and broad clinical adoption of Signatera. | Announcements from Natera regarding the initiation of 'multiple additional interventional studies' under the SIGNAL program over the next few months (H2 2026). | The launch of several new SIGNAL studies in H2 2026 is a bullish signal, indicating strong investment in future evidence generation and market expansion; fewer or delayed launches would be a bearish signal. | Natera press releases, SEC filings, and future earnings conference calls. ClinicalTrials.gov for newly registered Natera-sponsored interventional studies. | ClinicalTrials.gov: Search for Natera-sponsored interventional studies, particularly those under the 'SIGNAL' program. | EvaluatePharma: Tracking of Natera's clinical trial pipeline and new study initiations. |
Key Reported Metrics, Reratings Triggers & ResultsWomen's Health is a core segment for Natera. Strong performance, especially overcoming seasonal softness, indicates successful product innovation (e.g., enhance
Upcoming print · 2026-11-05
| Key reported metrics | ||
|---|---|---|
| Metric | Last period | Why it matters |
| Women's Health Revenue Growth | high-single-digit growth | Women's Health is a core segment for Natera. Strong performance, especially overcoming seasonal softness, indicates successful product innovation (e.g., enhanced Panorama) and market share gains, contributing to diversified growth. |
| Total Revenue Growth (ex revenue true-ups) | 40% | This metric reflects Natera's overall top-line performance, excluding non-recurring adjustments. It indicates the underlying strength of the business across all segments and is a key indicator of financial health. |
| Signatera Clinical MRD Units Growth | 56% | Signatera is Natera's key oncology product and a major growth driver. Continued strong growth in clinical MRD units indicates increasing adoption and market leadership, directly impacting future revenue. |
Key QuestionsWill Natera's Signatera clinical MRD units achieve sequential growth exceeding the previous record of 25,000 units in Q3 2026, following the exceptional Q2 perf
Will Natera's Signatera clinical MRD units achieve sequential growth exceeding the previous record of 25,000 units in Q3 2026, following the exceptional Q2 performance?
- Question 2
Can Natera achieve a sequential increase in Signatera's average selling price (ASP) in Q3 2026, potentially reaching the $25 upside case from tactical reimbursement improvements, or will it remain stable as guided?
- Question 3
Will Natera successfully complete full enrollment for its pivotal FIND study for early cancer detection in Q3 2026 as planned, maintaining the timeline for a 2027 readout and future commercialization?
Earnings Transcript Summary
· 2026Q2 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. **Expanding Signatera adoption and indications**: Management highlighted the FDA approval of Signatera as a companion diagnostic, Japanese PMDA approval, NCCN Category 1 recommendation for bladder cancer, and new submissions, all driving commercial adoption and future growth. The SIGNAL program for interventional studies further emphasizes this focus. 2. **Innovation and product development across core segments**: The launch of the enhanced Panorama test in women's health, continued success of Fetal Focus and fetal RHD, ongoing R&D investments in MRD, organ health, and women's health, and significant investment in the early cancer detection (ECD) FIND study demonstrate a strong focus on maintaining a cutting-edge product portfolio. 3. **Improving gross margins and average selling prices (ASPs)**: Management discussed efforts in revenue cycle management for Signatera, aiming for more consistent reimbursement from Medicare Advantage and commercial plans, and the potential for MolDX coverage decisions and broader guideline inclusion to drive ASPs towards a long-term target of $2,000. They also noted COGS improvements as new products scale. | Call Takeaway & ToneTakeaway: Natera reported an exceptionally strong second quarter of 2026, marked by record test volumes, robust revenue growth, and significant regulatory and clinical achievements, particularly for its Signatera oncology product. The company significantly raised its full-year revenue guidance, reflecting strong confidence in its commercial execution and product pipeline. Continued investments in R&D and clinical evidence are expected to drive future growth and margin expansion. Tone: The tone of the call was overwhelmingly positive and confident. Management expressed excitement about the company's performance, momentum, and strategic positioning, using phrases like "exceptional quarter," "on a roll," and "very strong momentum." They conveyed a clear vision for continued leadership and market expansion across their key business segments. | Prior Quarter'S Y/Y Growth By SegmentTotal Revenue: 39% year-over-year growth in Q1 2026. Oncology (Clinical Oncology Units): 55% year-over-year growth in Q1 2026. Women's Health: Q1 2026 saw "excellent volume performance" and "strong quarterly unit growth" contributing to the overall 39% revenue growth, but a specific y/y revenue percentage was not provided. Organ Health: Contributed to overall revenue growth in Q1 2026, but no specific y/y percentage was provided. | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. **Sustainability and drivers of Signatera volume growth**: Puneet Souda (Leerink Partners) asked for more detail on what was powering the remarkable growth and if it was sustainable. Management (Steven Chapman) attributed it to a "halo effect" from FDA approval, significant prior investments in commercial and medical affairs teams, large-scale clinical trials, cutting-edge technology, peer-reviewed evidence, and improved user experience. He acknowledged the 34k sequential growth was a "blowout record" but expected to outperform the previous record of 25k, with Q3 starting strong. 2. **Signatera ASP trajectory**: Daniel Brennan (TD Cowen) inquired if the recent sequential ASP increases ($25, $22) indicated a potential acceleration beyond the current guide. Management (Michael Brophy) stated the current guide assumes a stable ASP of $12.75 for the rest of the year. He suggested an upside case of another $25 in the near term from tactical improvements (Medicare Advantage compliance, biomarker state coverage). However, the larger, "transformational" impact on ASPs towards the $2,000 long-term target is expected in 2027 from MolDx indication coverage and broader guideline inclusions. 3. **Impact of competition on the MRD market**: David Westenberg (Piper Sandler) asked about the effect of other MRD competitors gaining traction on Natera's strong growth. Management (Steven Chapman) acknowledged competition but stated it's not a new dynamic and Natera has consistently performed well. He emphasized Natera's continued success is due to investments in technology, clinical studies, and a strong market position. He noted the market is very large, with Natera's penetration still in the "mid-single digits," implying ample room for growth despite competitors. | Revenue SegmentsTotal Revenue: approximately 38% year-over-year growth (approximately 40% year-on-year growth excluding revenue true-ups). Oncology (Clinical MRD units): approximately 56% year-over-year growth compared to Q2 2025. Women's Health: high-single-digit growth versus Q2 of last year. Organ Health: strong quarter, volume continued to ramp (no specific y/y percentage given). |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) | Hiring |
|---|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketSignatera became the first MRD test to get US FDA approval as a companion diagnostic and the first MRD test to get Japanese PMDA approval. The NCCN Guideline Committee issued a Category 1 recommendation for Signatera guided adjuvant treatment in muscle invasive bladder cancer. The newly enhanced Panorama test was launched, bringing the overall no call rate down to 0.5% and resulting in many new account wins. The final Medicare LCD for organ transplant surveillance (Prospera) was published, representing a meaningful expansion over the initial CMS proposal. Signatera received IVDR certification in the EU, indicated across more than 20 tumor types, streamlining future clinical trial launches and setting up for future reimbursement in Europe. A new submission to the Japanese PMDA for Signatera as a companion diagnostic in bladder cancer is underway. The SIGNAL-ER101 study, the first interventional prospective study sponsored by Natera, is open for early-stage HR positive HER2 negative breast cancer, representing a large addressable population. The pivotal FIND study for early cancer detection is approaching full enrollment, with expectations for a growth wave from 0 to millions of tests per year once launched. Submissions for 7 additional indications to MolDx are in progress, estimated to contribute $150 to $200 to the ASP. | About CompetitionNatera acknowledges persistent competition, noting that major oncology competitors have had MolDx-approved MRD tests on the market for several years. The company believes its extensive clinical evidence generation acts as a competitive moat, making it difficult for new entrants to replicate. In women's health, Natera believes it is in the best competitive position it has been in, benefiting from share gains due to recent product enhancements. Despite competition, Natera states that because the market is so large, competition does not have a significant impact on them, as they are still in the mid-single digits for overall market penetration. | About The Broader IndustryThe company believes the industry is 'crossing the sort of tipping point in the field where doctors are really starting to believe in MRD as a core part of their practice.' | Where Things Are HeadedNatera is resetting its revenue guidance to $2.85 billion to $2.91 billion, implying 31% annual growth ex true-ups. The company expects Signatera ASPs to grow substantially over time, with a long-term target of $2,000. They are comfortable about reaching 70%+ gross margin longer term, driven by major events like MolDx coverages and internal COGS projects. The pace of prospective study readouts is expected to accelerate meaningfully over the next few years, with the SIGNAL program launching multiple additional interventional studies covering significant portions of the largest tumor histologies. The FIND study for early cancer detection is on track to read out in 2027, with expectations for 'enormous future potential' and a 'growth wave from 0 currently to millions of tests per year.' MolDx indication coverage and guidelines in additional indications are expected to drive ASPs meaningfully higher in 2027. The company plans to 'keep our foot on the gas and invest in future growth.' | Updates On ThemeDiagnostics | Broader Themes EmergingAI and automation are being deployed 'across the business at a at a pretty frenetic pace' to drive efficiencies and automate workflows, allowing employees to move up the value chain. | Bullish-Leaning Quotes (Short)We had an exceptional quarter. We are clearly on a roll. This broad based acceleration is happening across tumor types. Maintaining this level of top line growth given the size of our revenue base is pretty remarkable. We are just now entering the harvest phase of an investment we began 7 years ago. We believe we are developing a genuinely differentiated product. new patients coming in for Signatera was way up. | Bearish-Leaning Quotes (Short)Q2 is typically our softest quarter for women's health due to seasonality. We do not expect to set a new volume record again in Q3. there is always going to be competition, and, you know, we have seen that I think if you if you look at you know, probably, you know, 4 years now, maybe 3+ years, there is been major oncology competitors that have had MRD tests that are approved by MolDx on the market. it is hard to forecast with precision. | HiringNatera made a significant investment in the size and breadth of its commercial team in the first half of 2025, and these new hires are now 'hitting their stride.' SG&A expenses are relatively stable in 2026 due to the successful commercial team expansion. The company is supplementing its distribution partner in Japan with direct sales and marketing efforts. AI and automation are being used to optimize workflows, allowing employees to move up the value chain in their large operations. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | Price Reaction |
|---|---|---|---|---|---|
| 2026-08-06 | Natera reported an exceptional Q2'26 with record test volumes, 56% Signatera growth, and significant regulatory wins (FDA CDx, PMDA, NCCN Category 1). Revenue grew 38%, and full-year guidance was raised by $100M. The market reacted very positively, with the stock returning 21.37% (t+2 days), significantly outperforming SPY, reflecting strong confidence in Natera's execution and future growth prospects. | Earnings Transcript | Mixed | +21.37% (vs SPY: +20.79%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| NTRA_be394610 | later this year | 2026-10-01 | 2026-12-31 | Commercial launch of Signatera for colorectal cancer in Japan. | This launch is expected to drive market adoption and revenue in Japan, supported by existing society guidelines. | Ticker | 2026-08-06 | earnings_transcript |